At the exchange meeting, Academician Ni Jiazuan first introduced the crisis and opportunities of nutrition and health industry at home and abroad, and introduced the advantages and scientific research achievements of his team in combination with the contents of the proposed cooperation between the two sides, and pointed out the difficulties and guiding suggestions for the proposed cooperation.
Dr. Liu Guangwei, director of Fukuyama Biomedical Department, reported the technical and product advantages of Fukuyama Bio. Since its establishment eight years ago, Fushan Bio has closely followed the changing trend of technological innovation in the global nutrition and health industry, devoted itself to research and development, and mastered the core technology of "targeted design and manufacturing of food nutrition". At present, the brand radish sulfur products with causal knowledge are undergoing clinical trials in many hospitals. At the same time, Fushan Bio owns the "synthesis and preparation technology of organic selenium small molecule drug lead compounds", and has synthesized more than 230 new organic selenium small molecule drug lead compounds for the first time in the world, and applied for 24 invention patents and 1 international patent (PCT) priority. The two sides will give full play to their respective advantages and cooperate in the research of innovative drugs and the research and development of nutritional targeted intervention products based on organic selenium derivatives of neuropathic diseases.
Subsequently, the two sides introduced and discussed specific cooperation topics and contents. Associate Professor Wang Yong from the Institute of Biochemistry of Shenzhen University introduced the research and accumulation of organic selenium in Fushan biological plants, and demonstrated the establishment and application of the detection method of selenium protein.
Lecturer Xiao Shifeng introduced the theoretical and technical basis of Tau protein aggregation and molecular dynamics model research of Fushan biological selenium source compounds from the aspect of Tau protein, the driving factor of Alzheimer's disease.
According to the preliminary research results of NSAIDs-SE derivatives provided by Fukuyama Bio, the protective effect of NSAIDs-Se derivatives on microglia inflammation of nervous system diseases, Professor Liu Qiong showed the primary screening model of selenium compounds on AD cells and animals, and evaluated the role and potential of selenium compounds from the aspects of intracellular oxidative stress, AD pathological related indicators, the curative effect of related drugs in the brain of mice, and the possible targets or pathways of drugs.
Recognizing their respective advantages and existing technical conditions, the two sides will reach a cooperation framework agreement as soon as possible and carry out relevant research. After the meeting, everyone visited the molecular biology laboratory of brain diseases of Shenzhen University.